Startups in the healthcare industry are embracing AI technology with the support of venture capital firms. Triomics, a San Francisco-based startup focused on accelerating cancer care with generative AI, recently announced a $15 million funding round from investors such as Lightspeed, Nexus Venture Partners, General Catalyst, and Y Combinator. Triomics has developed a family of large language models (LLMs) called OncoLLM to simplify the complex workflows involved in determining the right treatment path for cancer patients.
Traditionally, nurses and cancer care staff manually review patient charts to identify relevant data points for treatment decisions. This process is time-consuming and can lead to delays in clinical care. Triomics aims to solve this problem by providing oncology-focused OncoLLM models that can be fine-tuned using each institution’s internal datasets. These models are then deployed through Triomics’ software offerings, such as Harmony and Prism, which integrate with health system electronic health records (EHRs) to streamline specific care workflows.
Triomics’ OncoLLM models have shown promising results in patient-trial matching and have outperformed larger open-source and proprietary LLMs, as well as qualified medical experts. The company has also developed another variant of OncoLLM (70B) that surpasses both GPT-4 and medical experts in terms of accuracy. These advancements in AI technology have the potential to greatly enhance cancer care and improve patient outcomes.
To further scale its operations and reach more institutions, Triomics plans to use the recent funding to expand its team across domains. The company aims to partner with over a dozen academic medical centers by the end of the year and has already started working with several institutions. Triomics’ pricing strategy is tailored to each customer, ensuring that the OncoLLM-based solution meets their specific needs.
Unlike other solutions in the market, Triomics’ specialization in oncology and its use of gen AI native technology set it apart. Many existing solutions rely on legacy technologies without the scalability and return on investment that the industry demands. Triomics’ focus on leveraging AI to improve cancer care holds great potential for transforming the healthcare landscape and positively impacting the lives of millions of patients.
In conclusion, the integration of AI technology in healthcare, particularly in the field of oncology, shows significant promise in streamlining workflows and improving patient outcomes. Startups like Triomics are at the forefront of this innovation, using generative AI models to revolutionize cancer care. With continued investment and collaboration with medical institutions, the future of AI in healthcare looks bright.